Saltar al contenido
Merck

Autophosphorylation on S614 inhibits the activity and the transforming potential of BRAF.

Cellular signalling (2016-06-28)
Layal Dernayka, Nora Rauch, Mohamed-Ali Jarboui, Armin Zebisch, Yves Texier, Nicola Horn, David Romano, Christian Johannes Gloeckner, Alex von Kriegsheim, Marius Ueffing, Walter Kolch, Karsten Boldt
RESUMEN

The BRAF proto-oncogene serine/threonine-protein kinase, known as BRAF, belongs to the RAF kinase family. It regulates the MAPK/ERK signalling pathway affecting several cellular processes such as growth, survival, differentiation, and cellular transformation. BRAF is mutated in ~8% of all human cancers with the V600E mutation constituting ~90% of mutations. Here, we have used quantitative mass spectrometry to map and compare phosphorylation site patterns between BRAF and BRAF V600E. We identified sites that are shared as well as several quantitative differences in phosphorylation abundance. The highest difference is phosphorylation of S614 in the activation loop which is ~5fold enhanced in BRAF V600E. Mutation of S614 increases the kinase activity of both BRAF and BRAF V600E and the transforming ability of BRAF V600E. The phosphorylation of S614 is mitogen inducible and the result of autophosphorylation. These data suggest that phosphorylation at this site is inhibitory, and part of the physiological shut-down mechanism of BRAF signalling.

MATERIALES
Número de producto
Marca
Descripción del producto

Millipore
Gel ANTI-FLAG® M2 Affinity, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Proteína MEK1, inactiva, 50 g, Unactive, N-terminal GST & C-terminal His6-tagged, recombinant full-length human MEK1, for use in Kinase Assays.